A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Signaling by epidermal growth factor receptor (EGFR) must be controlled tightly because aberrant EGFR activity may cause cell transformation. Receptor-associated late transducer (RALT) is a feedback inhibitor of EGFR whose genetic ablation in the mouse causes phenotypes due to EGFR-driven excess cell proliferation. RALT inhibits EGFR catalytic activation by docking onto EGFR kinase domain. We report here an additional mechanism of EGFR suppression mediated by RALT, demonstrating that RALT-bound EGF receptors undergo endocytosis and eventual degradation into lysosomes. Moreover, RALT rescues the endocytic deficit of EGFR mutants unable to undergo either endocytosis (Dc214) or degradation (Y1045F) and mediates endocytosis via a domain distinct from that responsible for EGFR catalytic suppression. Consistent with providing a scaffolding function for endocytic proteins, RALT drives EGFR endocytosis by binding to AP-2 and Intersectins. These data suggest a model in which binding of RALT to EGFR integrates suppression of EGFR kinase with receptor endocytosis and degradation, leading to durable repression of EGFR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Kinase inhibition by RALT, but not by AG1478, is associated to normal rates of EGFR endocytosis and down-regulation. (A) Expression of EGFR and MYC-RALT was reconstituted in NR6 fibroblasts, which lack endogenous EGFR expression. Control and RALT-overexpressing NR6-EGFR cells were rendered quiescent and then stimulated with 100 ng/ml EGF (±3 µM AG1478) for the indicated time. Lysates were immunoblotted as indicated. (B) Control (±3 µM AG1478) and MYC-RALT–expressing NR6-EGFR cells were assayed for [125I]-EGF uptake (1 ng/ml at 37°C for the indicated time). The graph reports the average results ± SD from four independent experiments. (C) Control (±3 µM AG1478) and MYC-RALT–expressing NR6-EGFR cells were made quiescent, incubated at 37°C with 100 ng/ml EGF for the indicated time, and processed to determine residual [125I]-EGF binding at the cell surface (percentage of binding at time 0). Results were averaged from three independent experiments ± SD. (D) EGFR degradation. Control and MYC-RALT–expressing NR6-EGFR cells were rendered quiescent and then stimulated with 100 ng/ml EGF for the indicated time (hours). Lysates were immunoblotted with the indicated antibodies. Two different exposures of the same anti-EGFR autoradiograph are shown. (E) Quiescent MYC-RALT–expressing NR6-EGFR cells were incubated with 20 ng/ml EGF on ice for 30 min. After EGF wash-out, cells were chased at 37°C in EGF-free medium for either 10 min (for EGFR/EEA1 and EGFR/RALT colocalization) or 30 min (for EGFR/LAMP-1 colocalization). Nuclei were stained with Hoechst 33258 (blue). Bar, 5 µm.](https://figures.cochat.ai/paper-figures/38d157a70ebb47519ae9968ec91095be/a-two-tiered-mechanism-of-egfr-inhibition-by-ralt-mig6-via-kinase-suppression-figure-1.jpg)
![Figure 2. RALT rescues the endocytic deficit of EGFR Dc214. (A) Quiescent control and MYC-RALT–expressing NR6-EGFR Dc214 cells were either left untreated or stimulated with 20 ng/ml EGF for 10 min at 37°C. Cells were fixed and stained with anti-EGFR mAb 108 (red) and Hoechst 33258 (blue). (B) MYC-RALT–expressing NR6-EGFR Dc214 cells were rendered quiescent and then incubated with 20 ng/ml EGF on ice for 30 min. After EGF wash-out, cells were chased at 37°C in EGF-free medium for 10 min, fixed, and stained for EGFR, EEA1, and MYC-RALT immunodetection. Nuclei were stained with Hoechst 33258 (blue). (C) NR6-EGFR Dc214 cells were transfected with either control or RALT-specific siRNAs. Cells were made quiescent by serum deprivation and then challenged with 10% newborn calf serum (NCS) for 3 h to induce RALT protein expression. After serum wash-out, cells were left untreated or stimulated with 20 ng/ml EGF for 10 min at 37°C before being processed for anti-EGFR staining (red). Nuclei were stained with Hoechst 33258 (blue). Sister cultures were lysed to monitor the efficiency of RALT KD by immunoblot (top). Nontransfected NR6-EGFR Dc214 cells (±NCS stimulation) were included as additional immunoblotting controls. β-Actin was used as loading control. (D) Control and RALT siRNA-transfected NR6 Dc214 cells were made quiescent and then stimulated with NCS as in C. After serum wash-out, cells were incubated with 1 ng/ml [125I]-EGF for 8 min at 37°C. Nontransfected cells (±NCS stimulation) were included as additional control. Columns report the average of three independent experiments ± SD. Bars: (A and C) 20 µm; (B) 5 µm.](https://figures.cochat.ai/paper-figures/794032fbf2e9439a9fbe02d4b419f8ee/a-two-tiered-mechanism-of-egfr-inhibition-by-ralt-mig6-via-kinase-suppression-figure-2.jpg)
![Figure 3. Relocation onto EGFR is required for RALT-mediated endocytosis. (A and B) Quiescent NR6-EGFR Dc214 cells expressing the indicated MYC-RALT alleles were assayed for [125I]-EGF uptake (1 ng/ml at 37°C for the indicated time). The graphs report average results ± SD from four (A) and three (B) independent experiments. (C and D) NR6-EGFR Dc214 cells expressing the indicated MYC-RALT alleles were made quiescent and then assayed for [125I]-EGF uptake (1 ng/ml for 8 min at 37°C) either before or after a 3-h stimulation with 10% NCS to induce RALT expression. Results were averaged ± SD from three independent experiments. Comparison between endogenous and ectopic RALT proteins indicates that the latter are largely overexpressed (see Fig. S2 A), thus allowing the assessment of their potential dominant-negative activity over endogenous RALT.](https://figures.cochat.ai/paper-figures/88cdcb7febd944629a036c09139f5ae5/a-two-tiered-mechanism-of-egfr-inhibition-by-ralt-mig6-via-kinase-suppression-figure-3.jpg)
![Figure 4. Identification of the RALT endocytic domain. (A) Schematic representation of chimeras generated by fusing the indicated fragments of RALT to the C-terminal end of EGFR1–682. (B) The indicated EGFR1–682-RALT chimeras (referred to as ER, see panel A) were expressed in NR6 cells. Quiescent cells were assayed for [125I]-EGF uptake (3 ng/ml for 5 min at 37°C). Columns report average results ± SD from four independent experiments. (C) Quiescent NR6 cells expressing either wt EGFR or ER144–323 were allowed to bind mAb 108 (3 µg/ml) for 30 min on ice either in the absence or presence of EGF (20 ng/ml). After mAb wash-out, cells were shifted to 37°C in mAb/EGF-free medium for 10 min. After fixation, cells were stained with anti–mouse IgG to visualize mAb 108 (red) and Hoechst 33258 (blue). (D) Quiescent NR6-ER144–323 cells were incubated for 30 min on ice with 3 µg/ml mAb 108. After mAb wash out, cells were chased for 10 min at 37°C in serum-free medium before being processed for mAb 108 and EEA1 immuno-imaging. Nuclei were stained with Hoechst 33258 (blue). Bars: (C) 20 µm; (D) 5 µm.](https://figures.cochat.ai/paper-figures/edfbb2dd348a4d68964d2b1480902525/a-two-tiered-mechanism-of-egfr-inhibition-by-ralt-mig6-via-kinase-suppression-figure-4.jpg)
![Figure 5. RALT drives degradation of EGFR Dc214 and EGFR Y1045F. (A) EGFR Dc214 down-regulation. Control and MYC-RALT–expressing NR6-EGFR Dc214 cells were made quiescent and assayed for receptor down-regulation as in Fig. 1 C. Graphs indicate the average results ± SD from three independent experiments. (B) [125I]-EGF degradation. Quiescent control and MYC-RALT–expressing NR6-EGFR Dc214 cells were allowed to bind [125I]-EGF on ice (15 ng/ml for 45 min). After washing, cells were shifted to 37°C in EGF-free medium for the indicated time. Degraded [125I]-EGF was measured as the fraction of TCA-soluble radioactivity (i.e., the sum of TCA-soluble cpm measured in cell lysates and extracellular medium) over bound [125I]-EGF. Results were averaged (±SD) from three independent experiments. Note that under these conditions EGF stimulation induces significant RALT expression in control NR6-EGFR Dc214 cells by 90 min (not depicted), which likely explains why in control cells [125I]-EGF degradation increases above background past the 1.5-h time point. (C) Quiescent MYC-RALT–expressing NR6-EGFR Dc214 cells were incubated with EGF on ice as in Fig. 2 B, washed, chased in EGF-free medium for 30 min at 37°C, and processed for EGFR, LAMP-1, and MYC-RALT immuno-imaging. Nuclei were stained by Hoechst 33258. (D) Top: control and MYC-RALT–expressing NR6-EGFR Y1045F cells were made quiescent and then stimulated with 100 ng/ml EGF for the indicated time. Where indicated, chloroquine was added to the culture medium throughout the EGF incubation time. Lysates were immunoblotted with the indicated antibodies. Two different exposures of the same anti-EGFR autoradiograph are shown. Bottom: sister plates were stimulated with 100 ng/ml EGF for 5 min at 37°C to document the extent of catalytic suppression of EGFR Y1045F by MYC-RALT. Blots were probed as indicated; AKT was used as loading control. (E) NR6 fibroblasts expressing either wtEGFR or EGFR Y1045F in the absence (Ctrl) or presence of ectopic MYC-RALT (RALT) were made quiescent and either left untreated or incubated with 20 ng/ml EGF for the indicated time (min). Anti-EGFR immunoprecipitates and total cell lysates were immunoblotted as indicated. Bar, 5 µm.](https://figures.cochat.ai/paper-figures/13372d0d26b54a718402496fd711060b/a-two-tiered-mechanism-of-egfr-inhibition-by-ralt-mig6-via-kinase-suppression-figure-5.jpg)
![Figure 6. RALT-mediated endocytosis is clathrin- and AP-2–dependent. (A) MYC-RALT–expressing HeLa cells were made quiescent and then incubated with 20 ng/ml EGF for 5 min at 37°C before MYC-RALT and CHC immunostaining. (B) NR6-EGFR Dc214 RALT cells were transfected with control and CHC-specific siRNAs. Cells were rendered quiescent and assayed for [125I]-EGF (1 ng/ml for 6 min at 37°C) and [125I]-Tf (0.5 µg/ml for 4 min at 37°C) uptake. Results were averaged ± SD from four independent experiments. The immunoblot documents the typical efficiency of CHC KD; β-actin was used as loading control. (C) CHO cells were transfected with either GFP or dominant-negative (DN) DYN2 K44A-GFP vectors along with either pcDNA3-EGFR + pCS2MT (left) or pcDNA3-EGFR Dc214 + pCS2MT-RALT (right). 2 d after transfection, cells were made quiescent and stimulated with 20 ng/ml EGF for 10 min at 37°C before being processed for anti-EGFR staining. Nuclei were stained with Hoechst 33258 (blue). (D) Quiescent NR6-EGFR Dc214 cells were incubated for 30 min at 37°C with either vehicle or 80 µM dynasore before being assayed for [125I]-EGF uptake (± dynasore) for 6 min at 37°C. Results were averaged ± SD from three independent experiments. (E) NR6-EGFR Dc214 cells were transfected with control and two different μ2-specific siRNAs. Cells were made quiescent and assayed for [125I]-EGF uptake (1 ng/ml for the indicated time at 37°C). Results were averaged ± SD from three independent experiments. The immunoblot documents μ2 KD, which causes also concomitant reduction of the β2 subunit, as reported previously (Johannessen et al., 2006); CHC was used as loading control. Bars, (A) 10 µm; (inset) 5 µm; (C) 20 µm.](https://figures.cochat.ai/paper-figures/d1420c0c87554c6eba510f45de2ab4c6/a-two-tiered-mechanism-of-egfr-inhibition-by-ralt-mig6-via-kinase-suppression-figure-6.jpg)
![Figure 7. ITSN recruitment by RALT is necessary for RALT-mediated endocytosis. (A) NR6-EGFR Dc214 cells were transfected with either control or ITSN-specific siRNAs. Cells were made quiescent before being tested for [125I]-EGF uptake (1 ng/ml for the indicated time at 37°C). An experiment representative of three independent experiments is shown. ITSN KD efficiency was documented by immunoblot (ITSN1, bottom) and RT-PCR (ITSN2, top; note that our anti-ITSN2 antibody does not react against the mouse protein). GAPDH was used as RT-PCR reaction control. (B and C) HEK 293 cells were transfected with either empty vector (Ctrl) or vectors directing the expression of the indicated EGFR1–682-RALT chimeras. Lysates were subjected to immunoprecipitation with anti-EGFR mAb 108 (B) and anti-ITSN2 antiserum (C). Total cell lysates (TCL, 5% of input lysate in IPs) and IPs were immunoblotted as indicated. (D) HEK 293 cells were cotransfected with vectors encoding HA-tagged 5SH3 X. laevis ITSN and the indicated MYC-RALT alleles. Cell lysates were immunoprecipitated with anti-HA antibodies and immunoblotted with anti-MYC 9E10 mAb. (E) EGFR Dc214 cells expressing comparable amounts of either wt or MYC-RALT 4Ala (see immunoblot) were made quiescent and assayed for [125I]-EGF uptake (1 ng/ml at 37°C). Columns report the endocytic rate constants Ke averaged from three independent experiments (0.131 ± 0.006 for wtRALT and 0.099 ± 0.013 for RALT 4Ala, P = 0.039).](https://figures.cochat.ai/paper-figures/65c85992d4d345c49a22131ce7129409/a-two-tiered-mechanism-of-egfr-inhibition-by-ralt-mig6-via-kinase-suppression-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“but also directs EGFR to the lysosomes for digestion for a longer-lasting inhibitory effect [48].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dynasore, a Cell-Permeable Inhibitor of Dynamin
Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C., & Kirchhausen, T. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.04.002 · Cited by 1,958
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 2×
“, 2003) and the intracellular catalytic domain of the receptor (Zhang et al., 2006).”
Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80231-2 · Cited by 1,001
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor
Levkowitz, G., Waterman, H., Zamir, E., Kam, Z., Oved, S., Langdon, W. Y., Beguinot, L., Geiger, B., & Yarden, Y. (1998) · Genes & Development · doi:10.1101/gad.12.23.3663 · Cited by 865
SH3 domains: complexity in moderation
Mayer, B. J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.7.1253 · Cited by 788
Endocytosis and intracellular trafficking of ErbBs
Sorkin, A., & Goh, L. K. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.029 · Cited by 756
Derailed endocytosis: an emerging feature of cancer
Mosesson, Y., Mills, G. B., & Yarden, Y. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2521 · Cited by 718
Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation
Haglund, K., Sigismund, S., Polo, S., Szymkiewicz, I., Di Fiore, P. P., & Dikic, I. (2003) · Nature Cell Biology · doi:10.1038/ncb983 · Cited by 715
Self-citationSigismund, S., Argenzio, E., Tosoni, D., Cavallaro, E., Polo, S., & Di Fiore, P. P. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.06.012 · Cited by 679
Self-citation
Cited by
Feedback regulation of EGFR signalling: decision making by early and delayed loops
Avraham, R., & Yarden, Y. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3048 · Cited by 672
Endocytosis of Receptor Tyrosine Kinases
Goh, L. K., & Sorkin, A. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a017459 · Cited by 461
Mellman, I., & Yarden, Y. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016949 · Cited by 394
Raf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
Role of lysosomes in physiological activities, diseases, and therapy
Zhang, Z., Yue, P., Lu, T., Wang, Y., Wei, Y., & Wei, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01087-1 · Cited by 356
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 344
Goh, L. K., Huang, F., Kim, W., Gygi, S., & Sorkin, A. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201001008 · Cited by 258
Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases
Mohapatra, B., Ahmad, G., Nadeau, S., Zutshi, N., An, W., Scheffe, S., Dong, L., Feng, D., Goetz, B., Arya, P., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.10.010 · Cited by 215
Lee, Y. S., Park, J. S., Kim, J. H., Jung, S. M., Lee, J. Y., Kim, S., & Park, S. H. (2011) · Nature Communications · doi:10.1038/ncomms1469 · Cited by 163
Glucocorticoids, genes and brain function
Juszczak, G. R., & Stankiewicz, A. M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.020 · Cited by 153
Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors
Segatto, O., Anastasi, S., & Alemà, S. (2011) · Journal of Cell Science · doi:10.1242/jcs.083303 · Cited by 103
Self-citationDeubiquitination of EGFR by Cezanne-1 contributes to cancer progression
Pareja, F. G., Ferraro, D. A., Rubin, C., Cohen‐Dvashi, H., Zhang, F., Aulmann, S., Ben‐Chetrit, N., Pines, G., Navon, R., Crosetto, N., et al. (2011) · Oncogene · doi:10.1038/onc.2011.587 · Cited by 116
Belle, N. M., Ji, Y., Herbine, K., Wei, Y. Q., Park, J., Zullo, K. M., Hung, L., Srivatsa, S., Young, T., Oniskey, T. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12315-1 · Cited by 98
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95
“It has been reported that ERRFI1 not only blocks EGFR’s activity by clamping onto its kinase domain to rapidly decrease EGFR signaling [47], but also directs EGFR to the lysosomes for digestion for a longer-lasting inhibitory effect [48].”
BackgroundFeedback regulation of RTK signaling in development
Neben, C. L., Lo, M., Jura, N., & Klein, O. D. (2017) · Developmental Biology · doi:10.1016/j.ydbio.2017.10.017 · Cited by 91
EGFR Trafficking in Physiology and Cancer
Caldieri, G., Malabarba, M. G., Fiore, P. P. D., & Sigismund, S. (2018) · Progress in molecular and subcellular biology · doi:10.1007/978-3-319-96704-2_9 · Cited by 90
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6
Park, E., Kim, N., Ficarro, S. B., Zhang, Y., Lee, B. I., Cho, A., Kim, K., Park, A. K.-J., Park, W., Murray, B. A., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3074 · Cited by 89
ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR
Thomas, C. G., Rajapaksa, G. K., Nikolos, F., Hao, R., Katchy, A., McCollum, C. W., Bondesson, M., Quinlan, P., Thompson, A. M., Krishnamurthy, S., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3358 · Cited by 87
Maity, T. K., Venugopalan, A., Linnoila, I., Cultraro, C. M., Giannakou, A., Nemati, R., Zhang, X., Webster, J. D., Ritt, D., Ghosal, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0750 · Cited by 73
Staal, B., Williams, B. O., Beier, F., Woude, G. F. V., & Zhang, Y.-W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400744111 · Cited by 61
Chapter Six - The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling
Conte, A., & Sigismund, S. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.03.002 · Cited by 60
Hopkins, S., Linderoth, E., Hantschel, O., Suarez-Henriques, P., Pilia, G., Kendrick, H., Smalley, M. J., Superti-Furga, G., & Ferby, I. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.08.001 · Cited by 54
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
Gelfo, V., Rodia, M. T., Pucci, M., Dall’Ora, M., Santi, S., Solmi, R., Roth, L. E., Lindzen, M., Bonafè, M., Bertotti, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12354 · Cited by 56
Pest, M. A., Russell, B. A., Zhang, Y., Jeong, J., & Beier, F. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38758 · Cited by 55
Menezes, S. V., Sahni, S., Kovačević, Ž., & Richardson, D. R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.776393 · Cited by 54
Emerging Roles for Intersectin (ITSN) in Regulating Signaling and Disease Pathways
Hunter, M., Russo, A., & O'Bryan, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14047829 · Cited by 47
Intersectin scaffold proteins and their role in cell signaling and endocytosis
Herrero-Garcia, E., & O’Bryan, J. P. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.10.005 · Cited by 49
Menezes, S. V., Kovačević, Ž., & Richardson, D. R. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006279 · Cited by 49
An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors
Carvalho, S., Lindzen, M., Lauriola, M., Shirazi, N., Sinha, S., Abdul-Hai, A., Levanon, K., Korach, J., Barshack, I., Cohen, Y. C., et al. (2015) · Oncogene · doi:10.1038/onc.2015.93 · Cited by 47
Shen, H., Ferguson, S. M., Dephoure, N., Park, R., Yang, Y., Volpicelli-Daley, L., Gygi, S., Schlessinger, J., & De Camilli, P. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-07-0637 · Cited by 44
The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors
Chang, X., Izumchenko, E., Solis, L. M., Kim, M. S., Chatterjee, A., Ling, S., Monitto, C. L., Harari, P. M., Hidalgo, M. M., Goodman, S. N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068966 · Cited by 45
Wang, N., Li, R., Feng, B., Cheng, Y., Guo, Y., & Qian, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042031 · Cited by 44
Downregulation of Mig‐6 in nonsmall‐cell lung cancer is associated with EGFR signaling
Li, Z., Dong, Q., Wang, Y., Qu, L., Qiu, X., & Wang, E. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20815 · Cited by 44
Siu, A., Virtanen, C., & Jongstra, J. (2011) · Oncotarget · doi:10.18632/oncotarget.386 · Cited by 42
Glucocorticoid-Induced Suppression of β-Cell Proliferation Is Mediated by Mig6
Colvin, E. S., Ma, H.-Y., Chen, Y., Hernandez, A. M., & Fueger, P. T. (2013) · Endocrinology · doi:10.1210/en.2012-1923 · Cited by 41
DNAJB1 negatively regulates MIG6 to promote epidermal growth factor receptor signaling
Park, S., Choi, H.-K., Seo, J. S., Yoo, J., Jeong, J., Choi, Y., Choi, K., & Yoon, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.07.024 · Cited by 40
Naudin, C., Chevalier, C., & Roche, S. (2016) · Oncotarget · doi:10.18632/oncotarget.6929 · Cited by 36
Pathways driving the endocytosis of mutant and wild-type EGFR in cancer
Hampton, K. K., & Craven, R. J. (2014) · Oncoscience · doi:10.18632/oncoscience.67 · Cited by 35
Shangguan, Y., Jiang, H., Pan, Z., Xiao, H., Tan, Y., Tie, K., Qin, J., Deng, Y. L., Chen, L., & Wang, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.546 · Cited by 35
Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells
Walsh, A. M., & Lazzara, M. J. (2013) · Journal of Cell Science · doi:10.1242/jcs.123208 · Cited by 35
Phosphatidylinositol 4,5-bisphosphate in the Control of Membrane Trafficking
Li, S., Ghosh, C., Xing, Y., & Sun, Y. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.49665 · Cited by 35
Differential Roles of Grb 2 and AP ‐2 in p38 MAPK ‐ and EGF ‐Induced EGFR Internalization
Grandal, M. V., Grøvdal, L. M., Henriksen, L., Andersen, M. H., Holst, M. R., Madshus, I. H., & van Deurs, B. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01322.x · Cited by 34
Migliore, C., Morando, E., Ghiso, E., Anastasi, S., Leoni, V. P., Apicella, M., Corà, D., Sapino, A., Pietrantonio, F., de Braud, F., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708746 · Cited by 31
Self-citationMojica, C. A., Ybañez, W. S., Olarte, K. C. V., Poblete, A. B. C., & Bagamasbad, P. (2020) · Endocrinology · doi:10.1210/endocr/bqaa082 · Cited by 31
Sasaki, M., Terabayashi, T., Weiss, S. M., & Ferby, I. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.064 · Cited by 31
Gene 33/Mig6/ERRFI1, an Adapter Protein with Complex Functions in Cell Biology and Human Diseases
Xu, D., & Li, C. (2021) · Cells · doi:10.3390/cells10071574 · Cited by 30
Lamberti, D., Cristinziano, G., Porru, M., Leonetti, C., Egan, J. B., Shi, C., Buglioni, S., Amoreo, C. A., Castellani, L., Borad, M. J., et al. (2018) · Hepatology · doi:10.1002/hep.30127 · Cited by 30
Self-citationMitogen-Inducible Gene 6 Triggers Apoptosis and Exacerbates ER Stress-Induced β-Cell Death
Chen, Y., Colvin, E. S., Maier, B. F., Mirmira, R. G., & Fueger, P. T. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1174 · Cited by 28
Sorkin, A. D., & Puthenveedu, M. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6528-7_1 · Cited by 29
ERRFI1 induces apoptosis of hepatocellular carcinoma cells in response to tryptophan deficiency
Cui, M., Liu, D., Xiong, W., Wang, Y., & Mi, J. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00666-y · Cited by 27
Biology using engineering tools: The negative feedback amplifier
Birtwistle, M. R., & Kölch, W. (2011) · Cell Cycle · doi:10.4161/cc.10.13.16245 · Cited by 26
Prg4 and Osteoarthritis: Functions, Regulatory Factors, and Treatment Strategies
Fu, P.-J., Zheng, S.-Y., Luo, Y., Ren, Z.-Q., Li, Z.-H., Wang, Y., & Lu, B. (2025) · Biomedicines · doi:10.3390/biomedicines13030693 · Cited by 25
Towards the emerging crosstalk: ERBB family and steroid hormones
D’Uva, G., & Lauriola, M. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.11.004 · Cited by 25
Anastasi, S., Lamberti, D., Alemà, S., & Segatto, O. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.001 · Cited by 24
Self-citationPark, S., Li, C., Zhao, H. L., Darżynkiewicz, Z., & Xu, D. (2016) · Oncotarget · doi:10.18632/oncotarget.6866 · Cited by 24
Gandhi, T. K. B., Lynn, J. L. S., Wee, S., Gunaratne, J., & Hong, W. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.11.006 · Cited by 23
Cancer-Type Regulation of MIG-6 Expression by Inhibitors of Methylation and Histone Deacetylation
Zhang, Y., Staal, B., Dykema, K. J., Furge, K. A., & Woude, G. F. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038955 · Cited by 22
Okuda, K., Umemura, A., Umemura, S., Kataoka, S., Taketani, H., Seko, Y., Nishikawa, T., Yamaguchi, K., Moriguchi, M., Kanbara, Y., et al. (2021) · Cancers · doi:10.3390/cancers13071515 · Cited by 21
DNA damage alters EGFR signaling and reprograms cellular response via Mre-11
Volman, Y., Hefetz, R., Galun, E., & Rachmilewitz, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-09779-5 · Cited by 21
Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes
Chen, Y., Colvin, E. S., Griffin, K. E., Maier, B. F., & Fueger, P. T. (2014) · Diabetologia · doi:10.1007/s00125-014-3311-z · Cited by 20
Overexpression of MIG-6 in the cartilage induces an osteoarthritis-like phenotype in mice
Bellini, M. R., Pest, M. A., Miranda-Rodrigues, M., Qin, L., Jeong, J., & Beier, F. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02213-z · Cited by 20
Furgason, J. M., Li, W., Milholland, B., Cross, E., Li, Y., McPherson, C. M., Warnick, R. E., Rixe, O., Stambrook, P. J., Vijg, J., et al. (2014) · Mutagenesis · doi:10.1093/mutage/geu026 · Cited by 18
Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1
Kan, Y., Paung, Y., Seeliger, M. A., & Miller, W. T. (2023) · Cells · doi:10.3390/cells12060900 · Cited by 17
MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma
Vu, H. L., Rosenbaum, S. R., Capparelli, C., Purwin, T. J., Davies, M. A., Berger, A. C., & Aplin, A. E. (2015) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.11.012 · Cited by 17
Yang, Y., Liu, Y., Guo, R., Fu, Y., Zhang, Z., Zhang, P., Zhou, P., Wang, T., Huang, T., Li, X., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21768-1 · Cited by 17
Mig-6 Inhibits Autophagy in HCC Cell Lines by Modulating miR-193a-3p
Qu, L., Tian, Y., Hong, D., Wang, F., & Zhong, H. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.66040 · Cited by 16
Mig-6 participates in the regulation of cell senescence and retinoblastoma protein phosphorylation
Milewska, M., & Kölch, W. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.05.003 · Cited by 14
Li, Z., Qu, L., Wen, H., Zhong, H., Xu, K., Qiu, X.-S., & Wang, E. (2014) · PubMed · Cited by 14
Chen, W., Zhong, H., Wang, X., Pang, Q., Zhuang, J., HU, J. L., Chen, Y., Hu, J., Liu, J., & Tang, J. Y. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26488 · Cited by 13
Shimizu, S., Kondo, J., Onuma, K., Coppo, R., Ota, K., Kamada, M., Harada, Y., Tanaka, Y., Nakazawa, M. A., Tamada, Y., et al. (2023) · Cancer Science · doi:10.1111/cas.15882 · Cited by 12
Milewska, M., Romano, D., Herrero, A., Guerriero, M. L., Birtwistle, M. R., Quehenberger, F., Hatzl, S., Kholodenko, B. Ν., Segatto, O., Kölch, W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129859 · Cited by 12
Self-citationFu, N., Sheng, Y., Fan, Z., Wu, Z., Li, L., Xi, R., Shi, X., Zhang, G., & Wang, F. (2025) · Advanced Science · doi:10.1002/advs.202411642 · Cited by 11
Cho, J. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.3.025 · Cited by 11
Zhang, Y., & Zheng, Q. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.03.028 · Cited by 10
Steering tumor progression through the transcriptional response to growth factors and stroma
Feldman, M. E., & Yarden, Y. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.05.036 · Cited by 10
Sun, M., Cai, J., Anderson, R. A., & Sun, Y. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.736041 · Cited by 10
Zhang, Y., & Woude, G. F. V. (2013) · InTech eBooks · doi:10.5772/54393 · Cited by 9
Wang, R., Iwakura, Y., Araki, K., Keino‐Masu, K., Masu, M., Wang, X., Takei, N., Higashiyama, S., & Nawa, H. (2013) · Scientific Reports · doi:10.1038/srep01402 · Cited by 9
Meseure, D., Alsibai, K. D., Vacher, S., Hatem, R., Nicolas, A., Callens, C., Lerebours, F., & Bièche, I. (2020) · Analytical Cellular Pathology · doi:10.1155/2020/9268236 · Cited by 8
Future Aspects of Tumor Suppressor Gene
Cheng, Y. (2013) · InTech eBooks · doi:10.5772/56471 · Cited by 8
Yamada, K., Yamanaka, S., Yamakoshi, H., Kohyama, A., Iwabuchi, Y., Kosako, H., & Sawasaki, T. (2025) · Communications Biology · doi:10.1038/s42003-025-08761-x · Cited by 7
Lin, C., Barletta, J. A., Nehs, M. A., Morris, Z. S., Donner, D. B., Whang, E. E., Jeong, J., Kimura, S., Moore, F. D., & Ruan, D. T. (2011) · Surgery · doi:10.1016/j.surg.2011.09.014 · Cited by 7
Pinto, B. F., Lopes, P. H., Trufen, C. E. M., Ching, A. T. C., Junqueira-de-Azevedo, I. L. M., Nishiyama, M. Y., Pohl, P., & Tambourgi, D. V. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03602-4 · Cited by 7
Takeda, K., Takata, T., Kawai, Y., Ishigaki, Y., & Kajinami, K. (2013) · Genes to Cells · doi:10.1111/gtc.12043 · Cited by 7
Decreased Mitogen Inducible Gene 6 (MIG-6) Associated with Symptom Severity in Children with Autism
Russo, A. (2014) · Biomarker Insights · doi:10.4137/bmi.s15218 · Cited by 7
Walsh, A. M., & Lazzara, M. J. (2014) · Integrative Biology · doi:10.1039/c3ib40176f · Cited by 7
Yi, S. A., Cho, D., Kim, S.-J., Kim, H., Choi, M. K., Choi, H. S., Shin, S., Yun, S., Lim, A., Jeong, J. K., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13717 · Cited by 6
Chen, Y., Lutkewitte, A. J., Basavarajappa, H. D., & Fueger, P. T. (2023) · Metabolites · doi:10.3390/metabo13050627 · Cited by 6
A pervasive role for MIG6 in restraining cell proliferation
Anastasi, S., Castellani, L., Alemà, S., & Segatto, O. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.182 · Cited by 6
Self-citationKan, Y., & Miller, W. T. (2022) · FEBS Letters · doi:10.1002/1873-3468.14505 · Cited by 5
Olmo-González, D., Zhou, M., Oliveira, N. G., Zhou, F., Yan, F., González, J., València-Clua, K., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Giménez-Capitán, A. A., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02998-z · Cited by 4
Anastasi, S., Alemà, S., & Segatto, O. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6528-7_14 · Cited by 4
Self-citationEndocytosis and Endosomal Sorting of Receptor Tyrosine Kinases
Sorkin, A. D., & Fortian, A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_7 · Cited by 4
Yang, Y., Lin, S., Lay, J., Cho, C.-Y., Jang, T., Ku, H., Yao, C., & Chuang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914879 · Cited by 4
SNARE-associated proteins and receptor trafficking
(2016) · Receptors & Clinical Investigation · doi:10.14800/rci.1377 · Cited by 4
Wang, H., Liu, H., Lu, G., Tang, X., Luo, S., Du, M., Christiani, D. C., & Wei, Q. (2024) · Cancer Medicine · doi:10.1002/cam4.70073 · Cited by 3
Tang, D., Wang, C.-F., Wang, J., Jing, X.-T., & Ma, J. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.105173 · Cited by 3
Kuznetsova, O. A., Lebedeva, A., Kavun, A., Belova, E., Fedyanin, M. Y., Mileyko, V., Ivanov, M. V., & Nosov, D. (2023) · PubMed Central · Cited by 2
Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator
Anastasi, S., Zhu, S.-J., Ballarò, C., Manca, S., Lamberti, D., Wang, L.-J., Alemà, S., Yun, C.-H., & Segatto, O. (2016) · Cell · doi:10.1016/j.cell.2016.05.009 · Cited by 2
Self-citationMitogen Inducible Gene-6 in Joint Health and Osteoarthritis
Bellini, M. R. (2020) · Scholarship@Western (Western University) · Cited by 2
Metadata
- Authors
- Frosi, Y., Anastasi, S., Ballarò, C., Varsano, G., Castellani, L., Maspero, E., Polo, S., Alemà, S., & Segatto, O.
- Affiliations
- Instituto Nazionale Tumori Regina Elena (IT)
- Institute of Cell Biology and Neurobiology (IT)
- Università degli studi di Cassino e del Lazio Meridionale (IT)
- IFOM (IT)
- University of Milan (IT)
- Corresponding author
- Segatto, Oreste
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2010-04-26
- Volume
- 189
- Issue
- 3
- Pages
- 557-571
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC2867293
- OpenAlex
- W2095775828
- Cited by
- 125
- References
- 51
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 3 · 2023: 9 · 2022: 5 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 9 · 2015: 9 · 2014: 16 · 2013: 15 · 2012: 6
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Cell Biology (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- MIG6, EGFR, epidermal growth factor receptor, receptor internalization, receptor degradation, lysosomal degradation, kinase inhibition, AP-2, intersectin, product inhibition, EGFR signaling, cell proliferation
- MeSH terms
- Animals, Cells, Cultured, Mutation, Phosphotransferases, Signal Transduction, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.